Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Double-blind, Placebo-controlled, Dose-escalation Phase I Clinical Study to Evaluate the Safety and Tolerability of BPR-30221616 Injection in Healthy Subjects

NCT06760455 is registered in ClinicalTrials.gov with Chengdu Brilliant Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06760455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06760455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Double-blind, Placebo-controlled, Dose-escalation Phase I Clinical Study to Evaluate the Safety and Tolerability of BPR-30221616 Injection in Healthy Subjects
Lead sponsor
Chengdu Brilliant Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
January 10, 2025
Completion date
December 5, 2026
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants